-
1
-
-
34250350040
-
Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
-
2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-87.
-
(2007)
J Hypertens. 2007
, vol.25
, pp. 1105-1187
-
-
-
2
-
-
0038460302
-
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report
-
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289:2560-72.
-
(2003)
JAMA
, vol.289
, pp. 2560-2572
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
Cushman, W.C.4
Green, L.A.5
Izzo, J.L.6
-
3
-
-
21744458247
-
Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005.
-
Marín R, De la Sierra A, Armario P, Campo C, Banegas JR, Gorostidi M. Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005. Med Clin (Barc). 2005;125:24-34.
-
(2005)
Med Clin (Barc)
, vol.125
, pp. 24-34
-
-
Marín, R.1
De la Sierra, A.2
Armario, P.3
Campo, C.4
Banegas, J.R.5
Gorostidi, M.6
-
4
-
-
0346131047
-
Estratificación del riesgo cardiovascular en hipertensión en atención primaria e impacto sobre el tratamiento antihipertensivo. Estudio DIORISC.
-
Barrios V, Campuzano R, Peña G, Guzman G, Ruilope LM. Estratificación del riesgo cardiovascular en hipertensión en atención primaria e impacto sobre el tratamiento antihipertensivo. Estudio DIORISC. Hipertensión. 2002;19:114-20.
-
(2002)
Hipertensión
, vol.19
, pp. 114-120
-
-
Barrios, V.1
Campuzano, R.2
Peña, G.3
Guzman, G.4
Ruilope, L.M.5
-
5
-
-
33847747887
-
Perfil de riesgo cardiovascular de los pacientes con hipertensión arterial no controlada. Estudio Control-Project.
-
Márquez E, Coca A, De la Figuera M, Divisón JA, Llisterri JL, Sobrino J, et al. Perfil de riesgo cardiovascular de los pacientes con hipertensión arterial no controlada. Estudio Control-Project. Med Clin (Barc). 2007;128:86-91.
-
(2007)
Med Clin (Barc)
, vol.128
, pp. 86-91
-
-
Márquez, E.1
Coca, A.2
De la Figuera, M.3
Divisón, J.A.4
Llisterri, J.L.5
Sobrino, J.6
-
6
-
-
34249339077
-
Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study
-
Epub ahead of print
-
Barrios V, Escobar C, Calderon A, Echarri R, Gonzalez-Pededl V, Ruilope LM. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J Hum Hypertens. 2007; [Epub ahead of print].
-
(2007)
J Hum Hypertens
-
-
Barrios, V.1
Escobar, C.2
Calderon, A.3
Echarri, R.4
Gonzalez-Pededl, V.5
Ruilope, L.M.6
-
7
-
-
12144286055
-
Control de la presión arterial en la población hipertensa española atendida en atención primaria. Estudio PRESCAP 2002
-
Llisterri JL, Rodríguez G, Alonso FJ, Lou S, Divisón JA, Santos JA, et al. Control de la presión arterial en la población hipertensa española atendida en atención primaria. Estudio PRESCAP 2002. Med Clin (Barc). 2004;122:165-71.
-
(2004)
Med Clin (Barc)
, vol.122
, pp. 165-171
-
-
Llisterri, J.L.1
Rodríguez, G.2
Alonso, F.J.3
Lou, S.4
Divisón, J.A.5
Santos, J.A.6
-
8
-
-
32644469451
-
Evolución del control de la hipertensión arterial en Atención Primaria en España. Resultados del estudio Controlpres 2003.
-
Coca A. Evolución del control de la hipertensión arterial en Atención Primaria en España. Resultados del estudio Controlpres 2003. Hipertensión. 2005;22:5-14.
-
(2005)
Hipertensión
, vol.22
, pp. 5-14
-
-
Coca, A.1
-
9
-
-
27144476440
-
Conducta del médico de atención primaria ante el mal control de la presión arterial.
-
Alonso FJ, Divisón JA, Llisterri JL, Rodríguez GC, Lou S, Banegas JR, et al. Conducta del médico de atención primaria ante el mal control de la presión arterial. Aten Primaria. 2005;36:204-10.
-
(2005)
Aten Primaria
, vol.36
, pp. 204-210
-
-
Alonso, F.J.1
Divisón, J.A.2
Llisterri, J.L.3
Rodríguez, G.C.4
Lou, S.5
Banegas, J.R.6
-
10
-
-
34547816455
-
Estrategias para un control eficaz de la hipertensión arterial en España. Documento de Consenso.
-
Coca, A, Aranda P, Bertomeu V, Bonet A, Esmatjes E, Guillén F, et al. Estrategias para un control eficaz de la hipertensión arterial en España. Documento de Consenso. Hipertensión. 2006;23:152-6.
-
(2006)
Hipertensión
, vol.23
, pp. 152-156
-
-
Coca, A.1
Aranda, P.2
Bertomeu, V.3
Bonet, A.4
Esmatjes, E.5
Guillén, F.6
-
11
-
-
0242654867
-
Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials
-
Blood Pressure Lowering Treatment Trialists' Collaboration
-
Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-35.
-
(2003)
Lancet
, vol.362
, pp. 1527-1535
-
-
-
12
-
-
22544437310
-
Blood pressure reduction and cardiovascular prevention: An update including the 2003-2004 secondary prevention trials
-
Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res. 2005;28:385-407.
-
(2005)
Hypertens Res
, vol.28
, pp. 385-407
-
-
Staessen, J.A.1
Li, Y.2
Thijs, L.3
Wang, J.G.4
-
13
-
-
42049093082
-
Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials
-
Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;28:326-34.
-
(2003)
BMJ
, vol.28
, pp. 326-334
-
-
Law, M.R.1
Wald, N.J.2
Morris, J.K.3
Jordan, R.E.4
-
14
-
-
0034992192
-
Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension
-
Ruzicka M, Leenen FH. Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs. 2001;61:943-54.
-
(2001)
Drugs
, vol.61
, pp. 943-954
-
-
Ruzicka, M.1
Leenen, F.H.2
-
16
-
-
0035054331
-
Pharmacoeconomics of hypertension management: The place of combination therapy
-
Ambrosioni E. Pharmacoeconomics of hypertension management: the place of combination therapy. Pharmacoeconomics. 2001;19:337-47.
-
(2001)
Pharmacoeconomics
, vol.19
, pp. 337-347
-
-
Ambrosioni, E.1
-
17
-
-
80052110337
-
The role of combination therapy in the treatment of hypertension
-
Ruilope LM, Coca A. The role of combination therapy in the treatment of hypertension. Blood Press Suppl. 1998;1:22-6.
-
(1998)
Blood Press Suppl
, vol.1
, pp. 22-26
-
-
Ruilope, L.M.1
Coca, A.2
-
18
-
-
0013171629
-
Low Dose Combination Therapy vs. High Dose Monotherapy in the Management of Hypertension
-
Neutel JM, Smith DH, Weber MA. Low Dose Combination Therapy vs. High Dose Monotherapy in the Management of Hypertension. J Clin Hypertens (Greenwich). 1999;1:79-86.
-
(1999)
J Clin Hypertens (Greenwich)
, vol.1
, pp. 79-86
-
-
Neutel, J.M.1
Smith, D.H.2
Weber, M.A.3
-
19
-
-
4444380286
-
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: The first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension
-
Jamerson KA, Bakris GL, Wun CC, Dahlof B, Lefkowitz M, Manfreda S, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004;17:793-801.
-
(2004)
Am J Hypertens
, vol.17
, pp. 793-801
-
-
Jamerson, K.A.1
Bakris, G.L.2
Wun, C.C.3
Dahlof, B.4
Lefkowitz, M.5
Manfreda, S.6
-
20
-
-
0042154108
-
Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)
-
Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563-74.
-
(2003)
J Hypertens
, vol.21
, pp. 1563-1574
-
-
Lindholm, L.H.1
Persson, M.2
Alaupovic, P.3
Carlberg, B.4
Svensson, A.5
Samuelsson, O.6
-
21
-
-
33845497759
-
STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome
-
Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, et al; STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29:2592-7.
-
(2006)
Diabetes Care
, vol.29
, pp. 2592-2597
-
-
Bakris, G.1
Molitch, M.2
Hewkin, A.3
Kipnes, M.4
Sarafidis, P.5
Fakouhi, K.6
-
22
-
-
34447109035
-
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension
-
Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:1-18
-
(2007)
Clin Ther
, vol.29
, pp. 1-18
-
-
Philipp, T.1
Smith, T.R.2
Glazer, R.3
Wernsing, M.4
Yen, J.5
Jin, J.6
-
23
-
-
34247471686
-
Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension
-
Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29:279-89.
-
(2007)
Clin Ther
, vol.29
, pp. 279-289
-
-
Poldermans, D.1
Glazes, R.2
Kargiannis, S.3
Wernsing, M.4
Kaczor, J.5
Chiang, Y.T.6
-
24
-
-
33847044811
-
Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients
-
Fogari R, Zoppi A, Derosa G, Mugellini A, Lazzari P, Rinaldi A, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21:220-4.
-
(2007)
J Hum Hypertens
, vol.21
, pp. 220-224
-
-
Fogari, R.1
Zoppi, A.2
Derosa, G.3
Mugellini, A.4
Lazzari, P.5
Rinaldi, A.6
-
25
-
-
34247263709
-
Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients. and during standing in hypertensive patients
-
De Champlain J, Karas M, Assouline L, Nadeau R, Leblanc AR, Dube B, et al. Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients. and during standing in hypertensive patients. J Clin Hypertens (Greenwich). 2007;9:168-78.
-
(2007)
J Clin Hypertens (Greenwich)
, vol.9
, pp. 168-178
-
-
De Champlain, J.1
Karas, M.2
Assouline, L.3
Nadeau, R.4
Leblanc, A.R.5
Dube, B.6
-
26
-
-
2142643146
-
Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension
-
Calvo C, Hermida RC, Ayala DE, Ruilope LM. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens. 2004;22:837-46.
-
(2004)
J Hypertens
, vol.22
, pp. 837-846
-
-
Calvo, C.1
Hermida, R.C.2
Ayala, D.E.3
Ruilope, L.M.4
-
27
-
-
2942635317
-
VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
-
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-31.
-
(2004)
Lancet
, vol.363
, pp. 2022-2031
-
-
Julius, S.1
Kjeldsen, S.E.2
Weber, M.3
Brunner, H.R.4
Ekman, S.5
Hansson, L.6
-
28
-
-
0037031270
-
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect
-
Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:643-5.
-
(2002)
Circulation
, vol.106
, pp. 643-645
-
-
Viberti, G.1
Wheeldon, N.M.2
-
29
-
-
0035818884
-
Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
-
Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75.
-
(2001)
N Engl J Med
, vol.345
, pp. 1667-1675
-
-
Cohn, J.N.1
Tognoni, G.2
-
30
-
-
0242490542
-
Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
-
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906.
-
(2003)
N Engl J Med
, vol.349
, pp. 1893-1906
-
-
Pfeffer, M.A.1
McMurray, J.J.2
Velazquez, E.J.3
Rouleau, J.L.4
Kober, L.5
Maggioni, A.P.6
-
31
-
-
0344373794
-
Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihipertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
-
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
-
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihipertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97.
-
(2002)
JAMA
, vol.288
, pp. 2981-2997
-
-
-
32
-
-
24644443331
-
ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial
-
Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366:895-906.
-
(2005)
Lancet
, vol.366
, pp. 895-906
-
-
Dahlof, B.1
Sever, P.S.2
Poulter, N.R.3
Wedel, H.4
Beevers, D.G.5
Caulfield, M.6
-
33
-
-
7744231805
-
CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: a randomized controlled trial
-
Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-25.
-
(2004)
JAMA
, vol.292
, pp. 2217-2225
-
-
Nissen, S.E.1
Tuzcu, E.M.2
Libby, P.3
Thompson, P.D.4
Ghali, M.5
Garza, D.6
-
34
-
-
0034718574
-
Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators
-
Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102:1503-10.
-
(2000)
Circulation
, vol.102
, pp. 1503-1510
-
-
Pitt, B.1
Byington, R.P.2
Furberg, C.D.3
Hunninghake, D.B.4
Mancini, G.B.5
Miller, M.E.6
|